Navigation Links
Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air
Date:11/5/2009

SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today that William Spencer, President and CEO of Imagenetix, will be presenting the Company's story at the 2nd annual LD MICRO Conference on Thursday, December 3rd, at 10:30 AM PST at the Luxe Sunset in Los Angeles.

About LD MICRO

LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. It is a non-registered investment advisor.

For more information on the list of presenting companies or to register for the event, please visit http://www.ldmicro.com or call (408) 457-1042

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates proprietary over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.

    Contact     Imagenetix Investor Relations     William P. Spencer
                (858)385-2797                     Chief Executive Officer
                                                  Imagenetix, Inc.
                                                  Tel: (858) 674-8455

SOURCE Imagenetix, Inc.


'/>"/>
SOURCE Imagenetix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Imagenetix, Inc. to Present at the 2009 RedChip New York Equities Conference
2. Imagenetix, Inc. Announces Interview With Bloomberg Radio
3. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
4. Imagenetix, Inc. Reports First Quarter 2010 Results
5. Imagenetix, Inc. Reports Second Quarter and Six Month Results
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. Imagenetix Reports Results of Offer to Extend Warrants
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Cepheid to Webcast Upcoming Financial Presentations
11. Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology'
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- UCHealth ( Aurora, Colorado ) becomes ... patient management. In addition to optimizing care coordination for ... lung, UCHealth looks to improve provider workflow by decreasing ... Stephanie Brown, RN , Thoracic Nurse Navigator, says, ... Excel spreadsheet, which was extremely arduous and susceptible to ...
(Date:2/16/2017)... 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, ... study showed that aerosolized KL4 surfactant reduced lung ... preclinical animal model. The Company believes that these ... evidence that supports the role of KL4 surfactant ...
(Date:2/15/2017)... ... 15, 2017 , ... Executive search firm, Slone Partners, announces ... Matt is a veteran life sciences and molecular diagnostics executive with extensive ... identifying inherited disease risk in future generations. In his new role, Matt will ...
(Date:2/15/2017)... WASHINGTON, Feb. 15, 2017  Vanda Pharmaceuticals Inc. ... results for the fourth quarter and full year ... an exceptional year for Vanda as we continued ... and secured long-term exclusivity for Fanapt," said Mihael ... addition, our emerging pipeline with important 2017 milestones ...
Breaking Biology Technology:
(Date:1/26/2017)... Jan. 26, 2017  Crossmatch, a leading provider of ... solution aimed at combatting fraud, waste and abuse in ... at the Action on Disaster Relief conference in ... for UN agencies and foreign assistance organizations throughout ... and abuse are a largely unacknowledged problem in the ...
(Date:1/24/2017)... 24, 2017  It sounds simple and harmless—an ... monitors vital signs and alerts parents on their ... saturation level drops. But pediatric experts argue that ... with no evidence of medical benefits, especially to ... aggressively to parents of healthy babies, promising peace ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 ... enhancing user experience and security for consumer electronics, ... next-generation payment processing systems and cybersecurity solutions, today ... banks, enterprises and financial institutions worldwide to bolster ... of the end-to-end secure user authentication platforms they ...
Breaking Biology News(10 mins):